

## ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

> Title of Invention

Fibroblast Growth Factor Receptors and Methods for Their

Application Number:

10/613413

Confirmation Number:

9443

First Named Applicant:

Matthew Sleeman

Attorney Docket Number: 11000.1037c5

Art Unit:

1614

Search string:

( 5942420 or 20020009776 or 20020037557 or

20020103125 or 20010016335 ).pn.

## **US Patent Documents**

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
	. 1	5942420	1999-08-24	Holtzman			

## **US Published Applications**

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class Subclass
RLi	1	20020009776	2002-01-24	Saris, et al.	A1	
RLi	2	20020037557	2002-03-28	Jing, et al.	A1	
Ris	3.	20020103125	2002-08-01	Ashkenazi, et al.	A1	
PL;	4	20010016335	2001-08-23	Young, et al.	Å1	

## Signature

Examiner Name	Date
Ruixiang L	6/2/2005

PTO/SB/08 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

S 3 - 1 - 1 - 1 - 1 - 1 - 1	IFORMATION DISCLOSURE TATEMENT BY APPLICANT  (use as many sheets as necessary)  Complete if Known  Application Number  10/613,413  Filing Date  July 3, 2003  First Named Inventor  Matthew Sleeman, et al.  Art Unit  1814 164 6					
•			Application Number	10/613,413		
1		Application Number 10/613,413  N DISCLOSURE BY APPLICANT  Filing Date July 3, 2003  First Named Inventor Matthew Sleeman, et al.  Art Unit 1844 1 (4 ( ))				
				First Named Inventor	Matthew Sleeman, et al./	8
(i	ise as many sheet:	s as necessary	<i>'</i> )	Art Unit	1814 1646	100
			•	Examiner Name	AIE	itthew Sleeman, et al.
Sheet	1	of	2	Attorney Docket Number	11000.1037c5	<b>. .</b>

	U.S. PATENT DOCMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1						
	2						
	3						

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines Where		
Initials* No.1		Country code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	of Cited Document	Relevant Passages or Relevant Figures Appear		
RLI	1	WO 98/49302	11-05-1998	Genetics Institute, Inc.			
	2	WO 99/10364	03-04-1999	Human Genome Sciences, Inc.			
	3	WO 99/21859	05-06-1999	Glaxo Group Limited		T	
	4	WO 01/70977 A2	09-27-2001	Amgen, Inc.		T	
V	5	WO 00/24756	05-04-2000	Human Genome Sciences, Inc.			
RLi	6	WO 01/49715 A2	07-12-2001	Genentech, Inc.		$\overline{}$	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
RLi 1		MAHER, PAMELA, *p38 Mitogen-activated Protein Kinase Activation is Required for Fibroblast Growth Factor-2-stimulated Cell Proliferation but Not Differentiation*, The Journal of Biological Chemistry, June 18, 1999, pp. 17491-17498, Vol. 274, No. 25.	
	2	BOUJU, SOPHIE, ET AL., "Molecular cloning and functional expression of a novel human gene encoding two 41-43 kDa skeletal muscle internal membrane proteins", BiochemJ., 1998, pp. 549-556, Vol. 335, Great Britain.	$\prod$
	3	GRUSS, HANS-JÜRGEN, and DOWER, STEPHEN, K., "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas", BLOOD, The Journal of the American Society of Hematology, June 15, 1998, pp. 3378-3404, Vol. 85, No. 12.	
	4 -	PIÉTU, GENEVIÈVE, ET AL., "Novel Gene Transcripts Preferentially Expressed in Human Muscles Revealed by Quantitative Hybridization of a High Density cDNA Array", Genome Research, 1996, 492-503, Vol. 6.	Ш
	5	BANNER, DAVID, W., ET AL., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation", Cell, May 7, 1993, pp. 431-445, Vol. 73.	Ш
	6	YASPO, MARIE-LAURE, ET AL., "Cloning of a Novel Human Putative Type Ia Integral Membrane Protein Mapping to 21q22.3", Genomics, April 1, 1998, pp. 133-136, Vol. 49.	Ш.
	7	HATTORI, M., ET AL., GenPept Accession No. CAB90552, submitted May 5, 2000.	Щ
	8	PIETU, G., ET AL., GenPept Accession No. AAC78827, submitted 1996.	Ш
	9	HAYETTE, S., ET AL., GenPept Accession No. AAC64321, submitted 1998.	Ш
	10	BAUER, H., ET AL., GenPept Accession No. AA009175, submitted 1994.  HEMMATI-BRIVANLOU, A., ET AL., GenPept Accession No. AAB30638 submitted November 3, 1994.	₩
	12	GIVOL, D., GenPept Accession No. CAA41209, submitted February 20, 1991.	++-
	13	SHI, D.L., ET AL., GenPept Accession No. CAA53271, submitted 1993.	++-
	14	KATOH, O., ET AL., GenPept Accession No. AAB25535, submitted 1993.	TT-
	15	BACHNER, D., ET AL., GenPept Accession No. CAB65272, submitted 1999.	11
	16	XU, J., ET AL., GenPept Accession No. AAF03400, submitted 1999.	$\Pi$
	17	CABIBBO, A., ET AL., GenPept Accession No. AAF20364, submitted 2000.	$\Pi$
	18	ISOGAI, T., ET AL., GenPept Accession No. BAA91786, submitted February 16, 2000.	Ш
<del> </del>	19	WILSON, R., ET AL., GenPept Accession No. AAB42225, submitted 1994.	
	20	RIBOLDI TUNNICLIFFE, G.R., ET AL., GenPept Accession No. AAC15584, submitted September, 1997.	
<b> </b>	21	BOUCHON, A., ET., GenPept Accession No. AAF69825, submitted 2000.	Щ
	_22	SHIBATA, T., GenPept Accession No. BAA18909, submitted April 8, 1994.	₩-
<del>   </del> -	23_	JANG, W., ET AL., GenPept Accession No. AAC83205, submitted 1999.	<b>!</b> !
<del> </del>	24	POUSTKA, A, ET AL., GenPept Accession No. CAB55955, submitted September, 1999.	#
<del>        -</del>	25 26	DEAR, T.N., ET AL., Swiss-Prot Accession No. P14730, submitted 1988.	#
┝╼╼╊╼╾┼	<del></del>	COGLIEVINA, M., ET A., Swiss-Prot Accession No. P53104, submitted 1997.	<b>↓</b>
<del> </del>	28	WETERMAN, M.A.J., ET AL., Swiss-Prot Accession No. Q14956, submitted 1995.	1-
<del>1</del>	<del>28</del>	NAGHPAL, S., ET AL., Swiss-Prott Accession No. Q99969, submitted October, 1997.  POUSTKA, A., ET AL., PIR Accession No. T17265, submitted October 15, 1999.	#-
01:	29	SHI, D.L., ET AL., PIR Accession No. S38579, submitted November, 1993.	4
	_ 29	oni, b.e., en Acc, en Accession No. 330378, Submitted November, 1893.	$\bot \downarrow$

RI.	30	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA184346, February 17, 1997.	
, ,	31	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. Al119658, September 2, 1998.	
	32	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No.AA231415, February 26, 1997.	200
	33	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA498840, July 1, 1997.	Misordy
	34	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA636311, 1996.	AT
	34	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. Al050489, July 9, 1998.	<b>3</b>
	35	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA921460, April 20, 1998.	E
	36	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. Al466595, March 9, 1999.	ES SUUS I U SIGN IN
	37	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. Al287088, November 24, 1998.	1.0
	38	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. W77540, June 20, 1996.	0
	39	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA646983, October 28, 1997.	(2)
	40	MARRA, M., ET AL., The WashU-HHM! Mouse EST Project, Accession No. Al116725, February 13, 1997.	7.00.7
A	41	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA475668, June 18, 1997.	301
RLi	42	KO, M.S.H., ET AL., Systematic analyses of genes expressed in fertilized mouse eggs (The ERATO/Doi Project University), Accession No. C86502, March 11, 1998.	at at Wayne State

Examiner Signature	Ruixiang	L	Date Considered	6/2/205
				·

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>2</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	· · · · · · · · · · · · · · · · · · ·
	Application Number	10/613,413	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	July 3, 2003	
OTATEMENT STATTEDAM	First Named Inventor	Matthew Sleeman, et al.	
(use as many sheets as negessary)	2004 Art Unit	1614 1646	
	Examiner Name	Ruixiang Li	
Sheet 1 of TRACE	MARTH Attorney Docket Number	11000.1037c5	

	U.S. PATENT DOCMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1						
	2						
	3						

ν.	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines Where			
Initials* No.1		Country code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM DD VOOV	of Cited Document	Relevant Passages or Relevant Figures Appear			
RLi	1	WO 99/6308 A	12/09/1999	Genetech, Inc.		Τ		
	2	WO 01/09327 A	02/08/2001	Human Genome Sciences, Inc.				
	3	WO 00/73454 A	12/07/2000	Genetech, Inc.		Π		
	4	WO 01/00673 A	01/04/2001	Millennium Pharm, Inc.		Π		
	5	WO 01/53312	07/26/2001	Hyseq, Inc.		Τ		
V	6	WO 01/53455 A	07/26/2001	Hyseq, Inc.		1		
RLi	7	WO 01/60991 A	08/23/2001	Incyte Genomics, Inc.				
	L							

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²				
RLi	1	SLEEMAN, M., ET AL., "Identification of a new 1-15, fibroblast growth factor receptor, FGFR5" 18-20 Gene, Elsevier Biomedical Press., Amsterdam, NL, June 2001, Vol. 271, No. 2, 27.					
			<del> -</del>				

Examiner Signature	Ruisiang	Lr	Date Considered	6/2/2005	
					بيتسند

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.